The early results of a trial to treat leukemia with a WT1 DNA vaccine looks promising,  according to a presentation at the DNA Vaccines 2012 conference in California by Christian Ottensmeier, the trial’s principal investigator and Professor of Experimental Cancer Research at the University of Southampton.

The interim results, from eight patients, are part of a phase II trial that will enroll 31 patients in its chronic myelogenous leukemia (CML) arm.  Ottensmeier

noted robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune responses, including those of the “killer T cells,” were detected. Antibody and T cell responses are strong signals of the DNA vaccine’s potential to treat the disease. 

read more

via Science 2.0 Read More…

Advertisements